Ellen C. Caniglia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ellen C. Caniglia has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
Gloria Mayondi
12 shared publicationsJoseph Makhema
12 shared publicationsModiegi Diseko
12 shared publicationsShahin Lockman
12 shared publicationsMompati Mmalane
11 shared publicationsRebecca Zash
11 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Elsevier in Fertility and Sterility
- Vol. 126 (2) , 407-417
Emulating a target trial of surgical removal of uterine fibroids on atherosclerotic cardiovascular disease
- 19 May 2026
- Published by Elsevier in Fertility and Sterility
- Vol. 126 (2) , 407-417
Open AccessEmulating a target trial of surgical removal of uterine fibroids on atherosclerotic cardiovascular disease
- Open Access
- 12 May 2026
- Published by Springer Nature in Current Epidemiology Reports
- Vol. 13 (1)
Target Trial Emulation for Non-Pharmaceutical Interventions: Methodological Challenges and Solutions
Purpose of Review: Target trial emulation is a methodological framework designed to emulate hypothetical randomized controlled trials using observational data, particularly when conducting actual trials is unethical or infeasible. Non-pharmaceutical interventions, such as dietary patterns, physical activity, and environmental exposures, require unique methodological considerations for target trial emulation compared to pharmaceutical interventions. In this review, we aim to familiarize researchers with the key methodological challenges involved in emulating target trials of non-pharmaceutical interventions and to offer evidence-based recommendations for addressing these challenges. Recent Findings: We outline the fundamental assumptions necessary for valid causal inference when emulating a target trial: consistency, exchangeability, and positivity. We examine why these assumptions are particularly challenging to uphold for non-pharmaceutical interventions compared to pharmaceutical exposures. Next, we review recent work on non-pharmaceutical interventions studied using target trial emulation and highlight five methodological challenges that threaten the validity of causal assumptions: ill-defined interventions, intervention heterogeneity, uncommon or infeasible strategies, unclear time zero, and periodic measurement with sustained adherence assumptions. We map each challenge to specific components of the target trial protocol. To demonstrate how these challenges manifest in practice, we present a case study of maternal dairy intake and risk of child allergies and conclude with practical recommendations for mitigating each challenge. Summary: The framework and strategies outlined in this review will enable researchers to rigorously apply target trial emulation to non-pharmaceutical interventions, shifting the focus from documenting associations to estimating causal effects and strengthening the role of observational research in guiding evidence-based population health research.
- 12 May 2026
- Published by Springer Nature in Current Epidemiology Reports
- Vol. 13 (1)
Open AccessTarget Trial Emulation for Non-Pharmaceutical Interventions: Methodological Challenges and Solutions
Purpose of Review: Target trial emulation is a methodological framework designed to emulate hypothetical randomized controlled trials using observational data, particularly when conducting actual trials is unethical or infeasible. Non-pharmaceutical interventions, such as dietary patterns, physical activity, and environmental exposures, require unique methodological considerations for target trial emulation compared to pharmaceutical interventions. In this review, we aim to familiarize researchers with the key methodological challenges involved in emulating target trials of non-pharmaceutical interventions and to offer evidence-based recommendations for addressing these challenges. Recent Findings: We outline the fundamental assumptions necessary for valid causal inference when emulating a target trial: consistency, exchangeability, and positivity. We examine why these assumptions are particularly challenging to uphold for non-pharmaceutical interventions compared to pharmaceutical exposures. Next, we review recent work on non-pharmaceutical interventions studied using target trial emulation and highlight five methodological challenges that threaten the validity of causal assumptions: ill-defined interventions, intervention heterogeneity, uncommon or infeasible strategies, unclear time zero, and periodic measurement with sustained adherence assumptions. We map each challenge to specific components of the target trial protocol. To demonstrate how these challenges manifest in practice, we present a case study of maternal dairy intake and risk of child allergies and conclude with practical recommendations for mitigating each challenge. Summary: The framework and strategies outlined in this review will enable researchers to rigorously apply target trial emulation to non-pharmaceutical interventions, shifting the focus from documenting associations to estimating causal effects and strengthening the role of observational research in guiding evidence-based population health research.
- Open Access
- 25 February 2026
- Published by Elsevier in Current Developments in Nutrition
- Vol. 10 (3)
Healthcare Providers’ Perceptions and Experiences of Prenatal Iron and Folic Acid Supplementation—A Qualitative Study in Botswana
- 25 February 2026
- Published by Elsevier in Current Developments in Nutrition
- Vol. 10 (3)
Open AccessHealthcare Providers’ Perceptions and Experiences of Prenatal Iron and Folic Acid Supplementation—A Qualitative Study in Botswana
- Open Access
- 1 February 2026
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 40 (2) , 245-247
Interpreting Impacts of Population‐Level Interventions in the Presence of Exposure Misclassification
- 1 February 2026
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 40 (2) , 245-247
Open AccessInterpreting Impacts of Population‐Level Interventions in the Presence of Exposure Misclassification
- Open Access
- 6 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (1) , e044014
Association Between Uterine Fibroids and Risk of Atherosclerotic Cardiovascular Disease
Background: Uterine fibroids and atherosclerotic cardiovascular disease (ASCVD) share biological pathways, yet whether risk of ASCVD is different among those with fibroids compared with those without remains unexplored in large US cohorts with longitudinal data. This study assessed the association between uterine fibroids and risk of incident ASCVD. Methods: A US population‐based cohort study was done using Optum’s de‐identified Clinformatics Data Mart Database (2000–2022). Follow‐up continued until an ASCVD event, disenrollment, incident fibroid diagnosis in controls, or June 30, 2022. Individuals with fibroids were exact age‐matched (1:5) to individuals without fibroids with an annual gynecologic claim. Incident ASCVD, a composite of coronary artery disease, cerebrovascular disease, and peripheral artery disease, was evaluated, including individual events (eg, myocardial infarction and ischemic stroke). Results: Among 450 177 individuals with fibroids and 2 250 885 controls (mean age: 41 years, SD 6.3), the 1‐year and 10‐year cumulative incidence (95% CI) of ASCVD was 0.74% (0.71–0.77) and 5.42% (5.18–5.67) for the fibroid group versus 0.30% (0.29–0.31) and 3.00% (2.90–3.11) for controls. Adjusted analyses showed an increased ASCVD risk in the fibroid group (1‐year risk ratio: 2.47 [95% CI, 2.32–2.61]; 1‐year risk difference, 0.41% [95% CI, 0.40–0.47]; 10‐year risk ratio, 1.81 [95% CI, 1.66–1.96]; 10‐year risk difference, 2.40% [95% CI, 2.07, 2.77]. The increased risk was consistent for all individual components of ASCVD. Results were consistent across race and ethnicity and age subgroup analyses and sensitivity analyses addressing measurement error. Conclusions: Uterine fibroids are associated with sustained increased ASCVD risks up to 10 years postdiagnosis, supporting targeted ASCVD prevention in this population.
- 6 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (1) , e044014
Open AccessAssociation Between Uterine Fibroids and Risk of Atherosclerotic Cardiovascular Disease
Background: Uterine fibroids and atherosclerotic cardiovascular disease (ASCVD) share biological pathways, yet whether risk of ASCVD is different among those with fibroids compared with those without remains unexplored in large US cohorts with longitudinal data. This study assessed the association between uterine fibroids and risk of incident ASCVD. Methods: A US population‐based cohort study was done using Optum’s de‐identified Clinformatics Data Mart Database (2000–2022). Follow‐up continued until an ASCVD event, disenrollment, incident fibroid diagnosis in controls, or June 30, 2022. Individuals with fibroids were exact age‐matched (1:5) to individuals without fibroids with an annual gynecologic claim. Incident ASCVD, a composite of coronary artery disease, cerebrovascular disease, and peripheral artery disease, was evaluated, including individual events (eg, myocardial infarction and ischemic stroke). Results: Among 450 177 individuals with fibroids and 2 250 885 controls (mean age: 41 years, SD 6.3), the 1‐year and 10‐year cumulative incidence (95% CI) of ASCVD was 0.74% (0.71–0.77) and 5.42% (5.18–5.67) for the fibroid group versus 0.30% (0.29–0.31) and 3.00% (2.90–3.11) for controls. Adjusted analyses showed an increased ASCVD risk in the fibroid group (1‐year risk ratio: 2.47 [95% CI, 2.32–2.61]; 1‐year risk difference, 0.41% [95% CI, 0.40–0.47]; 10‐year risk ratio, 1.81 [95% CI, 1.66–1.96]; 10‐year risk difference, 2.40% [95% CI, 2.07, 2.77]. The increased risk was consistent for all individual components of ASCVD. Results were consistent across race and ethnicity and age subgroup analyses and sensitivity analyses addressing measurement error. Conclusions: Uterine fibroids are associated with sustained increased ASCVD risks up to 10 years postdiagnosis, supporting targeted ASCVD prevention in this population.
- Open Access
- 4 January 2026
- Published by BMJ in BMJ Paediatrics Open
- Vol. 10 (1) , e002098
Prevalence of major structural congenital abnormalities detected on infant surface examination in Botswana, 2014–2022: a birth outcomes surveillance study
Background: Population-level research focused on major congenital abnormalities (MCAs) in sub-Saharan Africa is needed. The Tsepamo study estimated the prevalence of MCAs evaluable on neonatal surface examinations in Botswana. Methods: Data were collected from up to 18 government hospitals throughout Botswana. Surface examinations were conducted by trained nurses after birth, and photographs and/or descriptions were used to identify and classify MCAs. Birth defects were categorised as MCAs if they were of clinical, surgical or cosmetic importance. We estimated MCA prevalence for all live and stillborn infants who were not exposed to HIV in utero. Variation by site, calendar year and season of MCAs (and, separately, of neural tube defects (NTDs)) was evaluated with the χ 2 and Benjamini-Hochberg methods. Results: There were 1066 newborns with at least one MCA (59.3 (95% CI 55.8 to 62.9) per 10 000 births). NTDs accounted for 112 (10.5%) MCAs (6.2 (95% CI 5.2 to 7.5) per 10 000 births). Limb defects accounted for the majority of the birth defects (32.4 (95% CI 29.9 to 35.1) per 10 000 births), followed by major nervous system defects (16.7 (95% CI 14.9 to 18.7) per 10 000 births). The most common individual MCA was talipes (clubfoot) (18.5 (95% CI 16.6 to 20.6) per 10 000 births). While there was no meaningful variability of total MCAs by calendar year or season of conception, there was notable variation of NTDs by these factors. Conclusions: The estimated prevalence of MCAs was 59.3 (95% CI 55.8 to 62.9) per 10 000 births. While NTD prevalence varied by calendar year and season of conception, overall MCA prevalence did not. Ongoing surveillance of MCAs is needed to monitor the occurrence of birth defects and support preventive interventions in Botswana and the region.
- 4 January 2026
- Published by BMJ in BMJ Paediatrics Open
- Vol. 10 (1) , e002098
Open AccessPrevalence of major structural congenital abnormalities detected on infant surface examination in Botswana, 2014–2022: a birth outcomes surveillance study
Background: Population-level research focused on major congenital abnormalities (MCAs) in sub-Saharan Africa is needed. The Tsepamo study estimated the prevalence of MCAs evaluable on neonatal surface examinations in Botswana. Methods: Data were collected from up to 18 government hospitals throughout Botswana. Surface examinations were conducted by trained nurses after birth, and photographs and/or descriptions were used to identify and classify MCAs. Birth defects were categorised as MCAs if they were of clinical, surgical or cosmetic importance. We estimated MCA prevalence for all live and stillborn infants who were not exposed to HIV in utero. Variation by site, calendar year and season of MCAs (and, separately, of neural tube defects (NTDs)) was evaluated with the χ 2 and Benjamini-Hochberg methods. Results: There were 1066 newborns with at least one MCA (59.3 (95% CI 55.8 to 62.9) per 10 000 births). NTDs accounted for 112 (10.5%) MCAs (6.2 (95% CI 5.2 to 7.5) per 10 000 births). Limb defects accounted for the majority of the birth defects (32.4 (95% CI 29.9 to 35.1) per 10 000 births), followed by major nervous system defects (16.7 (95% CI 14.9 to 18.7) per 10 000 births). The most common individual MCA was talipes (clubfoot) (18.5 (95% CI 16.6 to 20.6) per 10 000 births). While there was no meaningful variability of total MCAs by calendar year or season of conception, there was notable variation of NTDs by these factors. Conclusions: The estimated prevalence of MCAs was 59.3 (95% CI 55.8 to 62.9) per 10 000 births. While NTD prevalence varied by calendar year and season of conception, overall MCA prevalence did not. Ongoing surveillance of MCAs is needed to monitor the occurrence of birth defects and support preventive interventions in Botswana and the region.
- Open Access
- 21 October 2025
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 40 (2) , 248-260
Safety of Antihypertensive Medication for the Management of Non‐Severe Gestational Hypertension Among Pregnant Individuals in Botswana—Emulating a Series of Target Trials
Background: Data on antihypertensive medication for non‐severe gestational hypertension may suffer from immortal time and selection bias. Emulating target trials can prevent these biases by aligning follow‐up with treatment initiation. Objectives: We estimated the safety of antihypertensive medication initiation for the treatment of non‐severe gestational hypertension on adverse birth outcomes in Botswana using sequential target trial emulation. Methods: Data from the Tsepamo study (2014–2022), capturing birth outcomes at government delivery sites in Botswana, was used to examine antihypertensive medication initiation ≥ 24 weeks gestation for non‐severe gestational hypertension (140–159 systolic or 90–109 diastolic blood pressure ≥ 20 weeks gestation without chronic hypertension). Sequential weekly target trial emulation compared initiation versus no initiation during 24–35 weeks' gestation on the risk of stillbirth and birth of infant small for gestational age (SGA), with secondary outcomes including very SGA, preterm birth, very preterm birth, neonatal death, and severe gestational hypertension. For each trial, eligible individuals were without chronic hypertension, had not previously initiated antihypertensive medication and had ≥ 2 non‐severe blood pressure readings, at least one within 1 week of trial start. Log‐binomial models estimated gestational week‐specific and pooled risk ratios (RR) with 95% confidence intervals (CI) using bootstrapping. Results: Of eligible individuals, there were 1676 antihypertensive initiator ‘person‐trials’ and 5211 non‐initiator ‘person‐trials’. In the pooled analysis, the adjusted RR for stillbirth and SGA comparing initiators to non‐initiators was 0.92 (0.68, 1.19) and 1.09 (0.97, 1.23), respectively. The pooled adjusted RR for secondary outcomes were: very SGA, 1.05 (95% CI 0.88, 1.25); preterm birth, 1.09 (95% CI 0.96, 1.22); very preterm birth, 1.05 (95% CI 0.78, 1.47); neonatal death, 1.23 (95% CI 0.68, 2.24); severe gestational hypertension, 0.88 (95% CI 0.74, 1.07). Conclusions: In this retrospective cohort study, antihypertensive medication initiation between 24 and 35 weeks' gestation for non‐severe gestational hypertension was not associated with increased risk of adverse birth outcomes.
- 21 October 2025
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 40 (2) , 248-260
Open AccessSafety of Antihypertensive Medication for the Management of Non‐Severe Gestational Hypertension Among Pregnant Individuals in Botswana—Emulating a Series of Target Trials
Background: Data on antihypertensive medication for non‐severe gestational hypertension may suffer from immortal time and selection bias. Emulating target trials can prevent these biases by aligning follow‐up with treatment initiation. Objectives: We estimated the safety of antihypertensive medication initiation for the treatment of non‐severe gestational hypertension on adverse birth outcomes in Botswana using sequential target trial emulation. Methods: Data from the Tsepamo study (2014–2022), capturing birth outcomes at government delivery sites in Botswana, was used to examine antihypertensive medication initiation ≥ 24 weeks gestation for non‐severe gestational hypertension (140–159 systolic or 90–109 diastolic blood pressure ≥ 20 weeks gestation without chronic hypertension). Sequential weekly target trial emulation compared initiation versus no initiation during 24–35 weeks' gestation on the risk of stillbirth and birth of infant small for gestational age (SGA), with secondary outcomes including very SGA, preterm birth, very preterm birth, neonatal death, and severe gestational hypertension. For each trial, eligible individuals were without chronic hypertension, had not previously initiated antihypertensive medication and had ≥ 2 non‐severe blood pressure readings, at least one within 1 week of trial start. Log‐binomial models estimated gestational week‐specific and pooled risk ratios (RR) with 95% confidence intervals (CI) using bootstrapping. Results: Of eligible individuals, there were 1676 antihypertensive initiator ‘person‐trials’ and 5211 non‐initiator ‘person‐trials’. In the pooled analysis, the adjusted RR for stillbirth and SGA comparing initiators to non‐initiators was 0.92 (0.68, 1.19) and 1.09 (0.97, 1.23), respectively. The pooled adjusted RR for secondary outcomes were: very SGA, 1.05 (95% CI 0.88, 1.25); preterm birth, 1.09 (95% CI 0.96, 1.22); very preterm birth, 1.05 (95% CI 0.78, 1.47); neonatal death, 1.23 (95% CI 0.68, 2.24); severe gestational hypertension, 0.88 (95% CI 0.74, 1.07). Conclusions: In this retrospective cohort study, antihypertensive medication initiation between 24 and 35 weeks' gestation for non‐severe gestational hypertension was not associated with increased risk of adverse birth outcomes.
- 12 August 2025
- Published by Wolters Kluwer Health in AIDS
- Vol. 39 (14) , 2103-2113
Target trials of preconception switch from nevirapine or efavirenz-based antiretroviral therapy to dolutegravir-based antiretroviral therapy on adverse birth and maternal outcomes
Objective: To compare the effect of preconception switching from nevirapine (NVP) and efavirenz (EFV) to dolutegravir (DTG) based antiretroviral therapy (ART) on adverse birth and maternal outcomes. Design: Two target trial emulations using the Tsepamo Birth Outcomes Surveillance Study in Botswana. Methods: Among individuals who initiated NVP or EFV, we compared those who switched to DTG with those who did not switch prior to pregnancy. We estimated adjusted risk ratios and 95% confidence intervals (95% CIs) for any adverse birth outcome (stillbirth, neonatal death, preterm delivery, or small-for-gestational-age), any severe adverse birth outcome (stillbirth, neonatal death, very preterm delivery, or very small-for-gestational-age), low (n = 1054) with nonswitchers ( n = 3163), risk ratios (95% CIs) were 0.81 (0.74–0.89) for any adverse birth outcome, 0.81 (0.68–0.96) for any severe adverse birth outcome, 0.74 (0.57–0.96) for early pregnancy weight less than 50 kg, 1.35 (1.15–1.59) for early pregnancy weight at least 80 kg, and 0.93 (0.82–1.06) for maternal hypertension. Comparing EFV to DTG switchers (n = 1,538) with nonswitchers ( n = 7227), risk ratios (95% CIs) were 0.99 (0.91–1.07) for any adverse birth outcome, 1.05 (0.91–1.22) for any severe adverse birth outcome, 0.93 (0.78–1.12) for early pregnancy weight less than 50 kg, 1.22 (1.06–1.39) for early pregnancy weight at least 80 kg, and 1.29 (1.14–1.45) for maternal hypertension. Conclusion: Preconception switch from NVP to DTG may reduce the risk of adverse maternal and infant outcomes. Switch from EFV to DTG had no clear associations with adverse infant outcomes but may increase the risk of maternal hypertension.
- 12 August 2025
- Published by Wolters Kluwer Health in AIDS
- Vol. 39 (14) , 2103-2113
Target trials of preconception switch from nevirapine or efavirenz-based antiretroviral therapy to dolutegravir-based antiretroviral therapy on adverse birth and maternal outcomes
Objective: To compare the effect of preconception switching from nevirapine (NVP) and efavirenz (EFV) to dolutegravir (DTG) based antiretroviral therapy (ART) on adverse birth and maternal outcomes. Design: Two target trial emulations using the Tsepamo Birth Outcomes Surveillance Study in Botswana. Methods: Among individuals who initiated NVP or EFV, we compared those who switched to DTG with those who did not switch prior to pregnancy. We estimated adjusted risk ratios and 95% confidence intervals (95% CIs) for any adverse birth outcome (stillbirth, neonatal death, preterm delivery, or small-for-gestational-age), any severe adverse birth outcome (stillbirth, neonatal death, very preterm delivery, or very small-for-gestational-age), low (n = 1054) with nonswitchers ( n = 3163), risk ratios (95% CIs) were 0.81 (0.74–0.89) for any adverse birth outcome, 0.81 (0.68–0.96) for any severe adverse birth outcome, 0.74 (0.57–0.96) for early pregnancy weight less than 50 kg, 1.35 (1.15–1.59) for early pregnancy weight at least 80 kg, and 0.93 (0.82–1.06) for maternal hypertension. Comparing EFV to DTG switchers (n = 1,538) with nonswitchers ( n = 7227), risk ratios (95% CIs) were 0.99 (0.91–1.07) for any adverse birth outcome, 1.05 (0.91–1.22) for any severe adverse birth outcome, 0.93 (0.78–1.12) for early pregnancy weight less than 50 kg, 1.22 (1.06–1.39) for early pregnancy weight at least 80 kg, and 1.29 (1.14–1.45) for maternal hypertension. Conclusion: Preconception switch from NVP to DTG may reduce the risk of adverse maternal and infant outcomes. Switch from EFV to DTG had no clear associations with adverse infant outcomes but may increase the risk of maternal hypertension.
- Open Access
- 7 July 2025
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 40 (2) , 177-186
The Invisible Burden: Examining the Impact of Exposure Misclassification in Epidemiologic Analyses of Uterine Fibroids
Background: Uterine fibroids, a common gynaecologic condition, are often underdiagnosed, potentially biasing results in epidemiologic studies due to measurement error. Objectives: To examine how varying sensitivity in detecting uterine fibroids impacts effect estimates, using the association with hypertension onset as an example. Methods: Three simulation studies were conducted ( N = 100,000), considering true population prevalences of uterine fibroids of 5%, 20% and 60%. The first study varied detection sensitivity between 0% and 100%. The second examined differential sensitivity by symptom status (asymptomatic vs. symptomatic). The third assessed differential sensitivity by racialised groups. Specificity remained fixed at 90%, and true risk ratios (RRs) for the association with hypertension were set at 1.3 and 1.8. Results: Decreasing sensitivity biased results towards the null, with low‐sensitivity methods (e.g., self‐report) showing the largest bias and high‐sensitivity methods (e.g., transvaginal ultrasonography) the least bias. At low fibroid prevalence (5%), even gold‐standard ascertainment introduced bias due to imperfect specificity, whereas this concern diminished at higher prevalence. Assuming a dose–response relationship between fibroids and hypertension based on symptom status, results remained biased towards the null unless sensitivity was 100% and prevalence was high (60%); bias was most pronounced at low prevalence. When only symptomatic fibroids were associated with hypertension, increasing sensitivity biased results away from the null by capturing more asymptomatic cases. Studies using low‐sensitivity methods may fail to identify a true effect among Black females while identifying it among White females, potentially exacerbating disparities. Detection bias, where those with fibroids are more likely to have hypertension detected, could result in bias away from the null. Conclusions: Underdiagnosis of uterine fibroids can bias results towards the null, particularly with self‐report or modest effect estimates, potentially obscuring true effects. When only symptomatic fibroids were associated with the outcome, the bias was away from the null. Results varied by symptom status and race, highlighting the need to prioritise sensitive ascertainment methods, employ sensitivity analyses and improve reliability across diverse gynecologic conditions and health disparities.
- 7 July 2025
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 40 (2) , 177-186
Open AccessThe Invisible Burden: Examining the Impact of Exposure Misclassification in Epidemiologic Analyses of Uterine Fibroids
Background: Uterine fibroids, a common gynaecologic condition, are often underdiagnosed, potentially biasing results in epidemiologic studies due to measurement error. Objectives: To examine how varying sensitivity in detecting uterine fibroids impacts effect estimates, using the association with hypertension onset as an example. Methods: Three simulation studies were conducted ( N = 100,000), considering true population prevalences of uterine fibroids of 5%, 20% and 60%. The first study varied detection sensitivity between 0% and 100%. The second examined differential sensitivity by symptom status (asymptomatic vs. symptomatic). The third assessed differential sensitivity by racialised groups. Specificity remained fixed at 90%, and true risk ratios (RRs) for the association with hypertension were set at 1.3 and 1.8. Results: Decreasing sensitivity biased results towards the null, with low‐sensitivity methods (e.g., self‐report) showing the largest bias and high‐sensitivity methods (e.g., transvaginal ultrasonography) the least bias. At low fibroid prevalence (5%), even gold‐standard ascertainment introduced bias due to imperfect specificity, whereas this concern diminished at higher prevalence. Assuming a dose–response relationship between fibroids and hypertension based on symptom status, results remained biased towards the null unless sensitivity was 100% and prevalence was high (60%); bias was most pronounced at low prevalence. When only symptomatic fibroids were associated with hypertension, increasing sensitivity biased results away from the null by capturing more asymptomatic cases. Studies using low‐sensitivity methods may fail to identify a true effect among Black females while identifying it among White females, potentially exacerbating disparities. Detection bias, where those with fibroids are more likely to have hypertension detected, could result in bias away from the null. Conclusions: Underdiagnosis of uterine fibroids can bias results towards the null, particularly with self‐report or modest effect estimates, potentially obscuring true effects. When only symptomatic fibroids were associated with the outcome, the bias was away from the null. Results varied by symptom status and race, highlighting the need to prioritise sensitive ascertainment methods, employ sensitivity analyses and improve reliability across diverse gynecologic conditions and health disparities.
- Open Access
- 4 December 2024
- Published by Springer Nature in BMC Public Health
- Vol. 24 (1) , 1-12
A qualitative assessment of barriers to iron and folic acid supplementation among pregnant women in Botswana
Antenatal iron and folic acid (IFA) supplementation remains an effective strategy in the prevention of maternal anemia and low birthweight and is universally recommended by WHO. However, uptake of IFA has varied globally due to challenges with acceptability, supply and distribution, counselling and knowledge, and access to health services. In Botswana, nearly one-third of pregnant women engaged in antenatal care do not receive IFA, despite it being standard of care. The objectives of this study were to assess knowledge of and barriers and facilitators to IFA supplementation before and during pregnancy. We conducted qualitative interviews with two key stakeholder groups at two different levels—the individual level (pregnant women) and the service delivery level (health care providers). Here, we present results from interviews with pregnant women at two representative antenatal clinic sites in Botswana in 2022. Pregnant women were motivated to be healthy and were knowledgeable about the benefits of supplementation during pregnancy to mothers and their infants; however, women knew more about the benefits of iron than folic acid. Most women were in favor of receiving IFA supplementation prior to pregnancy and receiving fortified foods. Several key barriers were identified: lack of supplement availability in the clinics, poverty, side effects, number of tablets, and adherence. Approaches to overcome these barriers included improving supplement availability, improving health education, increasing supply of nutritious and fortified foods, backyard gardens, and increasing family and monetary support. Our study identified a need to 1) increase the availability of supplementation at antenatal clinics and 2) improve education regarding supplementation to include information about the benefits of folic acid and other micronutrients. Implementation research is needed to ascertain whether increasing supply and improving education could increase utilization of supplementation during pregnancy, with the ultimate goal of improving maternal and infant outcomes.
- 4 December 2024
- Published by Springer Nature in BMC Public Health
- Vol. 24 (1) , 1-12
Open AccessA qualitative assessment of barriers to iron and folic acid supplementation among pregnant women in Botswana
Antenatal iron and folic acid (IFA) supplementation remains an effective strategy in the prevention of maternal anemia and low birthweight and is universally recommended by WHO. However, uptake of IFA has varied globally due to challenges with acceptability, supply and distribution, counselling and knowledge, and access to health services. In Botswana, nearly one-third of pregnant women engaged in antenatal care do not receive IFA, despite it being standard of care. The objectives of this study were to assess knowledge of and barriers and facilitators to IFA supplementation before and during pregnancy. We conducted qualitative interviews with two key stakeholder groups at two different levels—the individual level (pregnant women) and the service delivery level (health care providers). Here, we present results from interviews with pregnant women at two representative antenatal clinic sites in Botswana in 2022. Pregnant women were motivated to be healthy and were knowledgeable about the benefits of supplementation during pregnancy to mothers and their infants; however, women knew more about the benefits of iron than folic acid. Most women were in favor of receiving IFA supplementation prior to pregnancy and receiving fortified foods. Several key barriers were identified: lack of supplement availability in the clinics, poverty, side effects, number of tablets, and adherence. Approaches to overcome these barriers included improving supplement availability, improving health education, increasing supply of nutritious and fortified foods, backyard gardens, and increasing family and monetary support. Our study identified a need to 1) increase the availability of supplementation at antenatal clinics and 2) improve education regarding supplementation to include information about the benefits of folic acid and other micronutrients. Implementation research is needed to ascertain whether increasing supply and improving education could increase utilization of supplementation during pregnancy, with the ultimate goal of improving maternal and infant outcomes.